Global Gene Therapy For Retinal Diseases Market | Know the Latest Innovations in the Industry

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gene Therapy For Retinal Diseases Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Request for Sample Pages:
According to the latest research study by InsightAce Analytic, the global gene therapy for retinal diseases market is expected to grow with a CAGR of 32.7% during the forecast period of 2020-2030. By region, North America and Europe dominated the global market.

Gene therapy is a technique of introducing genes into host cells to treat a disease. The tremendous potential of gene therapy to treat various ocular diseases is boosting the global demand for gene therapies for retinal diseases. With limited treatment options for inherited retinal diseases, gene therapy has been established as a safe, feasible, and effective treatment.

Get Free Sample Copy of Report :
https://www.insightaceanalytic.com/request-sample/1157

The growth of the gene therapy for retinal diseases market can be attributed to several factors, such as the growing adoption of gene therapy for retinal disorders, high prevalence of chronic and retinal diseases, growing geriatric population, increasing number of clinical trials for retinal gene therapies, and their positive results, growing demand for effective treatments, and the increasing government funding for healthcare research. The rising prevalence of diabetes across all countries is propelling the number of retinal diseases such as diabetic retinopathy, diabetic macular edema, etc. According to the National Eye Institute (NEI), by 2030 and 2050, approximately 10 & 14 million people respectively are expected to suffer from diabetic retinopathy in America. This emergence of retinal diseases is increasing R&D activities, leading to the innovation and adoption of gene therapy for retinal disorders, likely to fuel the market growth over the estimated timeframe.

However, expensive gene therapies are expected to limit the market growth during the forecast period.

Regionally, North America is projected to hold the highest market share during the forecast years 2020-2030, followed by Europe, owing to the fast adoption of advanced therapy techniques, the significant presence of research institutes and biopharmaceutical companies, and the well-established healthcare infrastructure.

Request for ToC/Proposal:
The key players operating in the gene therapy for retinal diseases market include Applied Genetic Technologies Corporation (US), Adverum Biotechnologies (US), ProQR Therapeutics (Netherlands), MeiraGTx Limited. (UK), Oxford BioMedica (UK), Horama S.A. (France), Gensight Biologics (France), Regenxbio Inc. (US), Spark Therapeutics, Inc. (US), Genzyme (Sanofi) (US), Novartis Pharmaceuticals (Switzerland), Nightstar Therapeutics (Biogen) (US), Hemera Biosciences (US) among others.

Key developments in the market:
In September 2021, Applied Genetic Technologies Corporation (AGTC) (US), a biotechnology company developing gene therapies for treating rare diseases, joined the My Retina Tracker Program as a new scientific collaborator. This initiative can enhance the development of its gene therapies for inherited retinal diseases (IRDs). The My Retina Tracker Program offers individuals with IRDs easy access to high-quality genetic diagnostics and genetic counseling.
In October 2020, Novartis (Switzerland) acquired Vedere Bio, a company developing next-generation ocular gene therapies. This acquisition builds on the company's commitment to cell and gene therapy. It will also enable Novartis to advance further its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
In June 2019, Oxford BioMedica (UK) and Santen Pharmaceutical, the market leader for prescription ophthalmic pharmaceuticals in Japan, agreed to jointly conduct R&D activities for gene therapy products. Under an R&D collaboration and an option and license agreement, the companies can use OXB's lentiviral vectors to generate pre-clinical, proof-of-concept evidence to innovate treatments for inherited retinal disease.

Market Segments
Global Gene Therapy For Retinal Diseases Market, by Indication, 2020-2030 (Valu US$ Mn)
Choroideremia (CHM)
Leber congenital amaurosis
Leber's hereditary optic neuropathy
X-linked retinitis pigmentosa
Other Indication

Global Gene Therapy For Retinal Diseases Market, by Region, 2020-2030 (Value US$ Mn)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America Gene Therapy For Retinal Diseases Market, by Country, 2020-2030 (Value US$ Mn)
U.S.
Canada

Europe Gene Therapy For Retinal Diseases Market, by Country, 2020-2030 (Value US$ Mn)
Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Gene Therapy For Retinal Diseases Market, by Country, 2020-2030 (Value US$ Mn)
India
China
Japan
South Korea
Australia & New Zealand

Latin America Gene Therapy For Retinal Diseases Market, by Country, 2020-2030 (Value US$ Mn)
Brazil
Mexico
Rest of Latin America

Middle East & Africa Gene Therapy For Retinal Diseases Market, by Country, 2020-2030 (Value US$ Mn)
GCC Countries
South Africa
Rest of Middle East & Africa

Why should buy this report:
To receive a comprehensive analysis of the prospects for the global gene therapy for retinal diseases market
To receive an industry overview and future trends of the gene therapy for retinal diseases market
To analyze the gene therapy for retinal diseases market drivers and challenges
To get information on the gene therapy for retinal diseases market size (Value US$ Mn) forecast to 2030
Major investments, mergers & acquisitions in the gene therapy for retinal diseases market industry

For More Information @
https://www.insightaceanalytic.com/report/global-gene-therapy-for-retinal-diseases-market-/1157

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Corporate Office :
Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com

info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

This release was published on openPR.